United States Cell Therapy Manufacturing Market to be Dominated by T-cell Therapies Segment Through 2028
The
growing burden of chronic diseases is expected to drive the growth of the United States Cell Therapy Manufacturing
Market in the forecast period 2024-2028.
According
to TechSci Research report, “United
States Cell Therapy Manufacturing Market - By Region, Competition Forecast and
Opportunities, 2018-2028,”
the United States Cell Therapy Manufacturing Market is anticipated to expand at
a remarkable rate during the forecast period of 2024-2028. The growth of this
industry is fueled by multiple factors. The establishment of a supportive
regulatory environment, including programs like the regenerative medicine
advanced therapy (RMAT) designation and expedited approval pathways, has made
the studies and commercialization of cell therapies easier. Growing public and
private sector support and investment in the industry have provided companies with
the means to increase their manufacturing capacity, invest in cutting-edge
technology, and accelerate the development of new treatments.
Clinical
trials significantly support the growth of cell therapy manufacturing in the
United States. These studies are essential for proving the long-term
effectiveness, safety, and advantages of treatments. They act as a boost for
market expansion and provide useful information for regulatory approval.
Clinical trials are still being conducted to examine the potential of cell
therapies for various diseases, including cancer, heart disease, and
neurological illnesses. The outcomes of these trials help broaden the
therapeutic uses of cell treatments and stimulate innovation in production
techniques.
The
cell therapy manufacturing market in the United States has been influenced by
several improvements. The field of personalized medicine is expanding,
resulting in the creation of patient-specific treatments like autologous cell
therapies. Advancements in gene editing technologies like CRISPR-Cas9 increase
the therapeutic potential of cell treatments by allowing precise adjustments to
cellular DNA. The incorporation of sophisticated manufacturing technologies,
including automation, robots, and closed-system processing, enhances
efficiency, reproducibility, and quality control. Collaborations between
academic institutions, research organizations, and industry stakeholders
promote innovation, technology transfer, and information exchange.
Browse
over XX market data Figures spread through XX Pages and an in-depth TOC on
"United States Cell Therapy Manufacturing
Market.”
The
United States Cell Therapy Manufacturing Market can be segmented by therapy, source
of cell, scale of operation, source, application, and end user (.
Based
on therapy, the market can be segmented into T-Cell Therapies, Dendritic Cell
Therapies, Tumor Cell Therapies, and Stem Cell Therapies. Due to several
important factors, T-cell therapies have become the dominant force in the
United States market for the production of cell therapies. T-cell therapies,
particularly chimeric antigen receptor T-cell (CAR-T) therapies, have proven to
be incredibly effective in treating certain cancers, including leukemia and
lymphoma. The effectiveness and potential for long-term remission have
attracted significant interest and funding from both researchers and
pharmaceutical firms. T cells are well-suited for precision medical approaches
due to their unique abilities, such as their capacity to identify and target
specific antigens. The production of T-cell treatments has become more
efficient and scalable due to advancements in gene editing technology and
well-established manufacturing techniques. T-cell treatments now hold a
significant share in the cell therapy manufacturing market, largely due to the
developed infrastructure, knowledge base, and regulatory environment in the
United States. These factors have propelled T-cell treatments to the forefront
of the field, revolutionizing cancer treatment and paving the way for further
advancements in cell-based therapies.
In
terms of application, the market can be divided into Oncology, Cardiovascular
Diseases, Orthopedic Diseases, and Others. The oncology segment dominates
the United States cell therapy manufacturing market. owing to the high demand
for novel treatments due to the incidence of cancer and the unmet medical
requirements it needs. Cell therapies, particularly CAR-T therapy, have shown
extraordinary success in treating several cancers, enabling long-lasting
remissions and even the possibility of a cure. The oncology segment has grown
as a result of the encouraging clinical results and strong regulatory focus on
speeding up the development and approval of oncology medicines. The development
of cell therapies in the field of oncology has also received substantial
funding and research efforts. The oncology niche's monopoly in the cell therapy
manufacturing sector is further supported by the country's well-established
infrastructure, expertise, and clinical trial networks. These elements help
maintain oncology's leadership position in the sector by fostering the ongoing
development and marketing of cell therapies specifically aimed at tackling the
complex problems presented by cancer.
Major
companies operating in the United States Cell Therapy Manufacturing Market
include:
- Lonza Group AG
- Thermo Fisher Scientific Inc.
- GE Healthcare Life Sciences
- Merck KGaA
- Fujifilm Holdings Corporation
- Novartis International AG
- Bristol Myers Squibb (BMS)
- Precision Biosciences Inc.
Download
Free Sample Report
Customers can also request for 10% free
customization on this report.
“Technology advances and ongoing
clinical trials are driving the enormous expansion of the cell therapy
manufacturing market in the United States. Gene editing, automation, and
bioprocessing are a few examples of technological advancements that have enhanced
manufacturing effectiveness, scalability, and product quality. Recent T-cell
therapy clinical trials have produced encouraging results, leading to the FDA's
approval of CAR-T treatments for some forms of leukemia and lymphoma. T-cell
treatments for solid tumors and other hematological malignancies are also being
investigated in clinical studies. With novel treatment options and improved
patient outcomes, these developments in clinical research and technology are
advancing the cell therapy manufacturing market in the United States,"
said Mr. Karan Chechi, Research Director with TechSci Research, a
research-based global management consulting firm.
“United
States Cell Therapy Manufacturing Market By Therapy (T-Cell Therapies,
Dendritic Cell Therapies, Tumor Cell Therapies, Stem Cell Therapies), By Source
of Cell (Autologous v/s Allogenic), By Scale of Operation (Preclinical,
Clinical, Commercial), By Source (In-House v/s Contract Manufacturing), By
Application (Oncology, Cardiovascular Diseases, Orthopedic Diseases, Others),
By End User (Pharmaceutical & Biotechnology Companies, Academic &
Research Institutes, Others), By Region, Competition Forecast &
Opportunities, 2028,” has evaluated the
future growth potential of United States Cell Therapy Manufacturing Market and
provides statistics & information on market size, structure, and future
market growth. The report intends to provide cutting-edge market intelligence
and help decision makers take sound investment decisions. Besides, the report
also identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in the United States Cell Therapy Manufacturing
Market.
Contact
Mr.
Ken Mathews
708
Third Avenue,
Manhattan,
NY,
New
York 10017
Tel:
+1-646-360-1656
Email: [email protected]
Website: www.techsciresearch.com